Medical Treatment for GIST Tumors

First-Line Treatment: Imatinib

The European Society for Medical Oncology recommends imatinib 400 mg daily as the primary medical treatment for unresectable or metastatic gastrointestinal stromal tumors (GISTs), with Level IA evidence 1, 2
For patients with KIT exon 9 mutations, the National Comprehensive Cancer Network recommends increasing the dose to 800 mg daily, given as 400 mg twice daily, as this mutation shows superior progression-free survival and overall survival at higher doses 1, 2
The British Journal of Cancer suggests continuing imatinib indefinitely as long as clinical benefit persists, since interruption leads to rapid tumor progression in most patients 1, 2, 3
The American Society of Clinical Oncology advises against using imatinib for PDGFRA exon 18 D842V mutant disease, as these tumors are inherently resistant to imatinib 1

The European Society for Medical Oncology recommends sunitinib as the standard second-line treatment when disease progresses on imatinib or if imatinib is not tolerated, with Level IA evidence 1, 2
The National Comprehensive Cancer Network suggests dosing options for sunitinib, including 50 mg daily for 4 weeks followed by 2 weeks off, or 37.5 mg daily continuously 1, 4
The Gastric Cancer journal notes that sunitinib shows particular benefit in patients with KIT exon 9 mutations and wild-type GISTs compared to those with KIT exon 11 mutations 5

The European Society for Medical Oncology recommends regorafenib 160 mg daily for 3 weeks out of every 4 weeks as the standard third-line therapy for patients progressing on both imatinib and sunitinib, with Level IA evidence 1, 2
The Gastric Cancer journal notes that regorafenib represents a multitarget inhibitor affecting KIT, PDGFR, VEGFR, FGFR, RET, and BRAF, with a clinical benefit rate approaching 50% and median progression-free survival of approximately 5 months 5

The British Journal of Cancer suggests that avapritinib is the most active treatment for PDGFRA D842V mutant GIST, though it is not currently approved by NICE and requires individual funding requests in the UK 1
The National Comprehensive Cancer Network recommends high-risk patients receive 3 years of adjuvant imatinib 400 mg daily after complete surgical resection, with Level IA evidence showing improved recurrence-free and overall survival 1, 2

The Gastric Cancer journal notes that rechallenge with imatinib after progression on sunitinib is an option, showing approximately twofold increase in progression-free survival compared to placebo 5, 2
The British Sarcoma Group guidelines suggest that continuation of TKI beyond RECIST progression lacks prospective evidence but may be considered on an individual basis if the patient derives clinical benefit 1

The National Comprehensive Cancer Network advises against interrupting imatinib for planned treatment holidays in the metastatic setting, as this dramatically increases progression risk 3, 2
The European Society for Medical Oncology recommends obtaining mutational analysis (KIT and PDGFRA) before initiating therapy, as mutation status predicts treatment response and guides optimal drug selection 1, 2